Overview of HIV/AIDS in GeorgiaOverview of HIV/AIDS in Georgia

Ketevan Mshvidobadze, MD, PhDKetevan Mshvidobadze, MD, PhD

Overview of HIV/AIDS in GeorgiaOverview of HIV/AIDS in Georgia

Ketevan Mshvidobadze, MD, PhDKetevan Mshvidobadze, MD, PhD

Women 524

Men 1526

05

1015

2025

3035

40

Distribution of HIV/AIDS Patients by Sex and Age GroupsDistribution of HIV/AIDS Patients by Sex and Age Groups

Age distribution

Infectious Diseases, AIDS Infectious Diseases, AIDS & Clinical Immunology& Clinical Immunology

Research CenterResearch Center

AIDS - 1044 Deaths - 440

HIV Cases Registered in Georgia AnnuallyHIV Cases Registered in Georgia AnnuallyN

um

be

r o

f ca

ses

Nu

mb

er

of

cas

es

Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center

1 3 1 6 0 6 2 8 2125 34

79 9395100

163

242276

344351

201

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

1 3 1 6 0 6 2 8 2125 34

79 9395100

163

242276

344351

201

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

Undetermined

1.4%

Mother to child transmission

2.3%

Homo/Bi-sexual contacts

2.7%

Blood transfusion

0.6%

Heterosexual contacts

33.4%

Injecting drug use

59.7%

Distribution of HIV Cases by Routes Distribution of HIV Cases by Routes

of Transmissionof Transmission

Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center

Universal Access Universal Access to HIV Treatment, Care and Support to HIV Treatment, Care and Support

and Preventionand Prevention

Georgia Is the First Among FSU Countries that from 2004

Ensured Universal (100%) Access to ARV Treatment.

Georgia Is the First Among FSU Countries that from 2004

Ensured Universal (100%) Access to ARV Treatment.

Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center

RUSRUS**

ARM*ARM*

KAZ*KAZ*

KGZ*KGZ*UZB*UZB*

TKMTKMTJK*TJK*

AZE*AZE*

BEL*BEL*

UKRUKR**

no HAART individuals on HAART (<1%) * in the process of scaling up ART

very poor access ( 1-25%) poor access (25-50%) disputed coverage estimates or

insufficient data available

moderate access (50-75%) good access (over 75%)

ALB* FYM*

GEOGEO

Access to HAART, 2008

National AIDS National AIDS

CenterCenter

Three Regional Three Regional

AIDS Treatment AIDS Treatment

CentersCenters

National AIDS National AIDS

CenterCenter

Three Regional Three Regional

AIDS Treatment AIDS Treatment

CentersCenters

TbilisiBatumi

Zugdidi

Kutaisi

Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center

Decentralisation of HIV Treatment Decentralisation of HIV Treatment and Care Process in Georgiaand Care Process in Georgia

Decentralisation of HIV Treatment Decentralisation of HIV Treatment and Care Process in Georgiaand Care Process in Georgia

ARV TreatmentARV Treatment

547 Patients are currently receiving ART

547 Patients are currently receiving ART

521 521 adultsadults521 521

adultsadults

26 26 childrenchildren

26 26 childrenchildren

Infectious Diseases, AIDS & Clinical Immunology Research Center

Salvage Regimens – WHO(Regimens for highly treatment experienced patients)

• Currently available: Enfurvitide (Fusion inhibitor) Darunavir (PI)

• Starting 2010 through extended Global Fund project: Raltegravir (Integrase inhibitor) Etravirine (NNRTI) Tipranavir (PI) Maraviroc (Entry inhibitor)

• Currently available: Enfurvitide (Fusion inhibitor) Darunavir (PI)

• Starting 2010 through extended Global Fund project: Raltegravir (Integrase inhibitor) Etravirine (NNRTI) Tipranavir (PI) Maraviroc (Entry inhibitor)

Infectious Diseases, AIDS & Clinical Immunology Research Center

Thank you